FLNA.US Filana Therapeutics, Inc.
- Market cap
- USD 21.4M
- P/E
- -
- P/B
- 0.39x
- ROE
- -68.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is FLNA.US undervalued?
Graham numberThe Graham number of Filana Therapeutics, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Filana Therapeutics, Inc. fundamental analysis
No fundamental analysis for Filana Therapeutics, Inc. yet.
Filana Therapeutics, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, In…
Full company profileFilana Therapeutics, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Filana Therapeutics, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -58.0K | -68.0K | -69.0K | -58.0K | -22.0K | - | - | - | - | -936K | - |
| Operating Income | -15.0M | -11.9M | -6.66M | -9.69M | -11.0M | -32.9M | -80.0M | -106M | -141M | -95.4M | -42.4M |
| EBITDA | -14.9M | -11.9M | -6.59M | -9.63M | -11.0M | -31.9M | -80.2M | -106M | -141M | -90.0M | -40.6M |
| Net Income | -14.9M | -11.9M | -6.56M | -4.63M | -6.33M | -32.4M | -76.2M | -97.2M | -24.3M | -91.0M | -39.5M |
| EPS | -2.28 | -1.82 | -0.61 | -0.27 | -0.24 | -0.82 | -1.90 | -2.32 | -0.01 | -1.88 | -0.82 |
| Balance Sheet | |||||||||||
| Total Assets | 19.3M | 10.8M | 20.1M | 23.5M | 94.3M | 267M | 235M | 152M | 158M | 118M | 100M |
| Total Liabilities | 665K | 1.13M | 511K | 1.39M | 2.10M | 12.9M | 7.30M | 14.2M | 11.8M | 44.0M | 42.1M |
| Shareholders' Equity | 18.6M | 9.70M | 19.6M | 22.1M | 92.2M | 254M | 228M | 137M | 146M | 74.4M | 58.0M |
| Cash & Short-term Investments | 18.7M | 10.5M | 19.8M | 23.1M | 93.5M | 233M | 201M | 121M | 129M | 95.5M | 47.0M |
| Total Debt | - | - | - | 90.0K | 293K | 236K | 139K | - | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -12.2M | -8.24M | -4.77M | -2.51M | -5.38M | -30.2M | -77.5M | -82.0M | -117M | -32.3M | -25.1M |
| Capital Expenditure | 75.0K | 0.00 | 0.00 | 18.0K | 0.00 | 22.2M | 2.71M | 414K | 103K | 581K | 69.3K |
| Free Cash Flow | -12.3M | -8.24M | -4.77M | -2.53M | -5.38M | -52.4M | -80.2M | -82.4M | -117M | -32.8M | -25.2M |
| Ratios | |||||||||||
| ROE | -79.7% | -122.8% | -33.4% | -21.0% | -6.9% | -12.8% | -33.5% | -70.7% | -16.7% | -122.3% | -68.2% |
| ROA | -76.9% | -110.0% | -32.6% | -19.7% | -6.7% | -12.1% | -32.5% | -64.1% | -15.5% | -76.9% | -39.5% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.00x | 0.00x | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Filana Therapeutics, Inc. dividends
Filana Therapeutics, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:7 on May 10, 2017.
Who owns Filana Therapeutics, Inc.
- Insiders 1.98%
- Institutions 24.27%
- Public & others 73.75%
- Shares outstanding 50.3M
- Free float 48.8M
Top funds holding FLNA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.37M | 2.73% | 0.00% | Sep 2026 |
| Fidelity Extended Market Index | 268K | 0.53% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 149K | 0.30% | 0.00% | Oct 2026 |
| Vanguard Health Care ETF | 134K | 0.27% | +0.12% | Sep 2026 |
| Fidelity Total Market Index | 81.5K | 0.16% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 72.5K | 0.14% | 0.00% | Sep 2026 |
| Goldman Sachs Absolute Ret Trckr Instl | 42.6K | 0.09% | +204.93% | Jun 2026 |
| Fidelity ZERO Total Market Index | 31.1K | 0.06% | 0.00% | Sep 2026 |
| Fidelity ZERO Extended Market Index | 27.5K | 0.05% | -5.83% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 15.9K | 0.03% | 0.00% | Sep 2026 |
| 1290 VT Micro Cap K | 10.0K | 0.02% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 9.09K | 0.02% | -77.25% | Aug 2026 |
| Fidelity Flex Small Cap Index | 7.56K | 0.02% | -24.77% | Aug 2026 |
| Fidelity VIP Extended Mkt Indx Initial | 3.50K | 0.01% | 0.00% | Sep 2026 |
Top institutions holding FLNA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Capital Management, LLC | 1.97M | 4.09% | +2.28% | Jun 2026 |
| Two Sigma Investments LLC | 1.71M | 3.54% | -13.95% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.60M | 3.31% | -20.62% | Jun 2026 |
| BlackRock Inc | 1.45M | 3.01% | +2.76% | Jun 2026 |
| The Goldman Sachs Group Inc | 669K | 1.38% | +1,518.41% | Jun 2026 |
| Geode Capital Management, LLC | 616K | 1.27% | +3.23% | Jun 2026 |
| D. E. Shaw & Co LP | 485K | 1.00% | -13.27% | Jun 2026 |
| GMT Capital Corp | 450K | 0.93% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 390K | 0.81% | +19.23% | Jun 2026 |
| Squarepoint Ops LLC | 318K | 0.66% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 316K | 0.65% | +15.32% | Jun 2026 |
| Acadian Asset Management LLC | 295K | 0.61% | +3.82% | Jun 2026 |
| Susquehanna International Group, LLP | 292K | 0.60% | -34.71% | Jun 2026 |
| GSA Capital Partners LLP | 269K | 0.56% | +23.67% | Jun 2026 |
| Group One Trading, LLC | 244K | 0.51% | -19.37% | Jun 2026 |
| State Street Corp | 209K | 0.43% | -12.87% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 133K | 0.27% | -0.07% | Jun 2026 |
| Connor Clark & Lunn Inv Mgmt Ltd | 132K | 0.27% | -3.38% | Jun 2026 |
| Federated Hermes Inc | 120K | 0.25% | +4.22% | Jun 2026 |
| Northern Trust Corp | 114K | 0.24% | -23.37% | Jun 2026 |
Filana Therapeutics, Inc. company profile
- Company name
- Filana Therapeutics, Inc.
- Ticker
- FLNA.US
- Exchange
- USA Stocks
- Listed since
- Jul 14, 2000
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Fiscal year end
- December
- Address
- 6801 N. Capital of Texas Highway, Austin, TX, United States, 78731
- Phone
- 512 501 2444
- Website
- filanatx.com
About Filana Therapeutics, Inc.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
Filana Therapeutics, Inc. management
10- Mr. Richard Jon BarryCEO, President & Director · born 1959
- Mr. Eric J. SchoenChief Financial Officer · born 1968
- Mr. R. Christopher Cook J.D.Chief Operating & Legal Officer · born 1964
- Dr. George Thornton Ph.D.Senior Vice President of Technology
- Mr. Michael ZamlootSenior Vice President of Technical Operations
- Jaren LandenChief Clinical Development Officer
- Dr. Angelique Bordey Ph.D.Senior Vice President of Neuroscience
- Mr. Jack Moore Ph.D.Senior Vice President of Clinical Development
- Dr. Joseph Hulihan M.D.Chief Medical Officer · born 1956
- Ms. Nancy TeasdaleHead of Regulatory Affairs